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Abstract: Neuropsychiatric systemic lupus erythematosus (NPSLE) is the least understood, yet perhaps the most preva-
lent manifestation of lupus.  The pathogenesis of NPSLE is multifactorial and involves various inflammatory cytokines, 
autoantibodies, and immune complexes resulting in vasculopathic, cytotoxic and autoantibody-mediated neuronal injury.  
The management of NPSLE is multimodal and has not been subjected to rigorous study. Different treatment regimens  
include nonsteroidal anti-inflammatory drugs, anticoagulation, and immunosuppressives such as cyclophosphamide, 
azathioprine, mycophenolate mofetil, and methotrexate.  For refractory NPSLE, intravenous immunoglobulin (IVIG), 
plasmapheresis, and rituximab have been used.  Adjunctive symptomatic treatment complements these therapies by target-
ing mood disorders, psychosis, cognitive impairment, seizures or headaches.  Several new biological agents are being 
tested including Belimumab, a human monoclonal antibody that targets B lymphocyte stimulator.  This review focuses  
on the pathophysiology, treatment, and new potential therapies for neuropsychiatric manifestations of systemic lupus 
erythematosus. 
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I. INTRODUCTION 
  An autoimmune disease is a disorder in which the misdi-
rected immune system reacts against host antigens. The dys-
regulation of the immune system may precipitate dysfunction 
and damage of various organ systems, including the central 
and peripheral nervous systems. We are reviewing patho-
physiology of neuropsychiatric involvement in systemic   
lupus erythematosus (SLE) and its therapy. Most of the clinical 
manifestations of disease are nonspecific complicating the 
diagnosis, clinical assessment and treatment planning. 
II. CLINICAL FEATURES AND EPIDEMIOLOGY 
  SLE is an autoimmune disease that predominantly affects 
women of child-bearing age. In the United States, SLE is 
more prevalent among African Americans, Hispanics, and 
Asians compared to non-Hispanic Caucasians [1]. This het-
erogeneous autoimmune disease is characterized by the loss 
of tolerance to autoantigens and the development of immune 
complexes that deposit in tissues and cause systemic in-
flammation. SLE also involves a number of cytokine path-
ways, including B lymphocyte stimulator (BLys), which 
promotes B-cell survival and autoantibody production, type I 
interferon (IFN), which acts as immune adjuvant, and tumor 
necrosis factor, which contributes to organ inflammation. 
Type I IFNs are normally produced by plasmacytoid den-
dritic cells in response to viral infection. However, patients 
with SLE have an increased expression of type I IFN regu-
lated genes due to the continuous production of IFN-. Their 
dendritic cells activated by immune complexes containing 
endogenous nucleic acids are also induced to synthesize IFN 
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that contributes to loss of tolerance and activation of autore-
active T and B cells with production of autoantibodies [2-4]. 
SLE patients have elevated serum levels of IFN-, which 
correlate with both disease activity and severity [5, 6]. Based 
on this knowledge, many clinical trials targeting cytokines as 
potential therapies for SLE are underway.  
  Neuropsychiatric lupus (NPSLE) is the least understood 
yet perhaps the most prevalent manifestations of lupus. It 
affects 14% to over 80% in adults [7-12] and 22% to 95% in 
children [11, 13-16] and can occur independently of active 
systemic disease and without serologic activity [17]. NSPLE 
is associated with increased morbidity and mortality [7-9, 18, 
19]. In 1999, the American College of Rheumatology (ACR) 
established case definitions for 19 specific neuropsychiatric 
syndromes, dividing them into two broad categories: central 
and peripheral as shown in Table 1 [20]. In NPSLE, cogni-
tive impairment is one of the most common manifestations, 
with a varying prevalence of 15% to 66% due to the differ-
ences in definition in the studies of mainly adult lupus pa-
tients [21-25]. Seizure and psychosis, however, are the only 
two NPSLE manifestations that comprise the neurologic 
component of the ACR classification criteria for SLE [26, 
27]. It is estimated that 28% to 40% of adult NPSLE mani-
festations develop before or around the time of the diagnosis 
of SLE and 63% occur within the first year after diagnosis 
[9, 19, 28]. 
III. PATHOPHYSIOLOGY AND PATHOGENESIS OF 
NEUROPSYCHIATRIC LUPUS 
  The pathogenesis of NPSLE is multifactorial and can 
involve various inflammatory cytokines, autoantibodies, and 
immune complexes resulting in vasculopathic, cytotoxic and 
autoantibody-mediated neuronal injury. The most common 
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pathy although not specific, which may due to complement 
activation and antiphospholipid antibodies [29]. Post mortem 
histopathologic studies in people with SLE have demon-
strated an array of pathologies including multifocal microin-
farcts, gross infarcts, hemorrhage, cortical atrophy, ischemic 
demyelination, and patchy multiple sclerosis–like demyeli-
nation [30]. 
Table  1.  Neuropsychiatric Syndromes of Systemic Lupus 
Erythematosus [11] 
Central Nervous System 
Aseptic meningitis 
Cerebrovascular disease 
Cognitive dysfunction 
Headache 
Movement disorder (Chorea) 
Seizures 
Acute confusional state 
Anxiety disorder 
Mood disorder 
Psychosis 
Demyelinating syndrome 
Myelopathy (transverse myelitis) 
Peripheral Nervous System 
Autonomic disorder 
Mononeuropathy 
Cranial neuropathy 
Plexopathy 
Polyneuropathy 
Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-
Barré syndrome) 
Myasthenia gravis 
 
  Disruption of the blood-brain barrier is integral to the 
neuropathology of SLE [31]. Endothelial cells responsible 
for maintenance of the blood-brain barrier may have altered 
function in the presence of elevated levels of ICAM-1, with 
subsequent normalization of function corresponding to both 
lower levels of ICAM-1 and disease remission [32]. Addi-
tionally, damage to the blood-brain barrier may be impli-
cated in corticosteroid-induced psychiatric disorders [33]. 
Diamond and colleagues have generated abundant evidence 
from murine models, supporting the role of circulating anti-
DNA autoantibodies mediating NPSLE via cross-reactivity 
with NR2 subunits of the anti-N-methyl-D-aspartate recep-
tors during a breach of blood-brain barrier from inflamma-
tion or stress [34-37]. This cross-reactive excitatory neuronal 
death in the hippocampus was non-inflammatory by histopa-
thologic examination and could be prevented by the admini-
stration of memantine, a NR2 glutamate receptor antagonist 
[36]. Similarly, epinephrine, a catecholamine, also breached 
the blood-brain barrier and caused selective neuronal loss in 
the lateral amygdala, leading to emotional disorder in the 
murine model [35]. These studies suggest that agents such as 
epinephrine can determine the region of brain that is made 
vulnerable to neurotoxic autoantibodies.  
  While interruption of the function of the blood-brain bar-
rier seems to play a role in the pathophysiology of NPSLE, 
there are several types of autoantibodies which are also asso-
ciated with NPSLE. In addition to the aforementioned anti-
NR2A glutamate receptor antibodies, intrathecal IgG produc-
tion is often elevated during a central nervous system flare, 
and then normalizes with the resolution of the flare [38, 39]. 
This fluctuation in IgG levels is in contrast to the persistent 
abnormal immunologic indices seen during a remission of 
multiple sclerosis [40]. Moreover, approximately 25% to 
40% of lupus patients have secondary antiphospholipid syn-
drome with clinical features of repeated episodes of arterial 
or venous thrombosis, recurrent spontaneous abortions, or 
thrombocytopenia in patients with antiphospholipid (aPL) 
antibodies [41-45]. Of note, patients with primary aPL syn-
drome do not fulfill the criteria for SLE, or other autoim-
mune disorders. APL antibodies target anionic phospholipids 
and protein-phospholipid complexes. Specifically, they can 
target negatively charged phosphatidyl glycerol, phosphati-
dyl serine, phosphatidyl acid, phosphatidyl inositol, and car-
diolipin, in addition to the neutrally charged phosphatidyl 
ethanolamine, phosphatidyl choline, platelet activating   
factor, and sphingomyelin [46]. Using ELISA and lupus   
anticoagulant tests, antibodies binding cardiolipin in the 
presence of 2-glycoprotein-1 and antibodies binding 2-
glycoprotein-1 and prothrombin can be detected. Studies 
have demonstrated aPL-mediated direct neuronal injury in 
the absence of ischemia [47-50]. Persistently elevated anti-
cardiolipin antibodies are associated with greater cognitive 
impairment [23, 24]. In a cohort of 1000 patients followed 
over 10 years, Cervera and colleagues demonstrated an in-
creased risk of thrombotic events, the most common being 
stroke which was observed in 11.8% of the cohort [51]. 
Among SLE patients with and without active disease both 
thrombotic events and cognitive impairment have been con-
sistently linked to the presence of aPL, such as lupus antico-
agulant and anticardiolipin antibodies [21, 52-54]. Addition-
ally, transverse myelitis is highly associated with the pres-
ence of aPL [55]. Significant correlations between anticardi-
olipin IgG antibodies and a reduction in psychomotor speed, 
and between anticardiolipin IgA antibodies and a reduction 
in conceptual reasoning and executive ability have been 
found [21]. While the role of these autoantibodies awaits 
elucidation, they certainly can act as proxies for disease 
markers which may aid in the diagnosis of NPSLE. 
  The pathophysiologic role of autoantibodies in NPSLE is 
under ongoing investigation. In particular, the previously 
mentioned anti-NR2 glutamate receptor antibodies are seen 
in 25% to 30% of patients with SLE and may also play a role 
in cognitive dysfunction and psychiatric disease [56, 57]. 
These antibodies are anti-DNA antibodies that cross-react 
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apoptotic cell death of neurons in vitro and in vivo [37]. The 
anti-ribosomal P antibodies, another potential contributors to 
the pathogenesis of NPSLE, have not been implicated in 
coexisting cognitive impairment [58, 59]. Some studies sug-
gested an association between serum anti-ribosomal P anti-
bodies and NPSLE syndromes of psychosis and depression 
[59-63]. An international meta-analysis of 1,537 patients 
with SLE found the negligible value of anti-ribosomal P an-
tibodies for the diagnosis of NPSLE or for specific NPSLE 
manifestations [64]. The potential role of anti-ribosomal P 
antibodies in the pathogenesis of NPSLE remains controver-
sial. A cellular protein found strictly in neurons and essential 
to the cytoskeletal integrity is MAP-2. In a study of 100   
patients with SLE and 74 patients with various neurologic 
disorders, more SLE patients comparing to neurologic in-
jury/disease control patients have presence of anti-MAP-2 
antibodies (17% vs. 4%, p=0.028 ) [65]. More specifically, 
76.5% of NPSLE had presence of serum anti-MAP-2 anti-
bodies. Using immunoproteomics, MAP-2B proteins were 
found to be preferentially recognized by sera from NPSLE 
patients, which further supports this association between the 
anti-MAP-2 antibodies and NPSLE [66]. The importance of 
autoantibodies is still under active investigation and many of 
the observations are based only on association.  
  Other possible intrathecal markers for NPSLE include 
matrix metalloproteinase-9 (MMP-9) and plasminogen acti-
vator inhibitor 1 (PAI-1). MMP-9 is secreted by cells found 
in the walls of the vasculature, including macrophages, T 
lymphocytes, endothelial cells, and smooth muscle [67]. Its 
primary function is to enhance T cell migration through con-
nective tissue. Significantly elevated intrathecal levels of 
MMP-9 are found in all patients with SLE comparing to non-
SLE patients and specifically, with more elevation in NPSLE 
patients when compared with SLE patients without NPSLE 
[68]. Furthermore, CSF levels of IL-6 and IL-8, which are 
found to be elevated in NPSLE, are both significantly corre-
lated with MMP-9 levels. Similarly, intrathecal levels of 
PAI-1 have been found to be significantly elevated in pa-
tients with NPSLE comparing to those without NPSLE and 
healthy controls [69]. The intrathecal levels of PAI-1 also 
correlated with CSF levels of proinflammatory cytokines, 
IL-6 and IL-8, in addition to association with neuronal dam-
age markers, glial fibrillary acidic protein and neurofilament 
triplet protein. The association between neuronal injury and 
intrathecal homeostasis imbalance contributed by the release 
of PAI-1 suggests a potential therapeutic role of anticoagula-
tion in patients with NPSLE even in the absence of the   
antiphospholipid syndrome. 
IV. NEUROIMAGING MODALITIES 
  Localizing the areas of the CNS associated with neuro-
psychiatric symptoms in SLE continues to be elucidated with 
brain imaging studies, though these modalities are not with-
out limitations. While focal neurologic symptoms of NPSLE 
correlate with conventional structural magnetic resonance 
imaging (MRI) abnormalities, abnormalities reflecting al-
tered perfusion or neurometabolite changes in NPSLE can be 
demonstrated by functional imaging techniques even in the 
absence of morphological lesions detectable by conventional 
MRI. Cortical atrophy, ventricular dilation, diffuse white 
matter, and gross infarctions are common [70-74]. Using 
structural MRI, 40%–80% of abnormalities in NPSLE are 
multiple discrete lesions concentrated in periventricular and 
subcortical white matter [75]. These can also be seen in SLE 
patients without past or active neuropsychiatric lupus [76]. 
Hippocampal atrophy correlates with disease duration, total 
corticosteroid dose, and repeat CNS events in patients with 
SLE [77]. The presence of hyperintense white matter lesions 
in SLE is associated with age, total corticosteroid dose re-
ceived and Systemic Lupus International Collaborating Clin-
ics (SLICC) Damage Index scores [78]. Furthermore, predic-
tors for development of new or worsening of existing white 
matter lesions include past CNS involvement, elevated titers 
of aPL antibodies, SLICC Damage Index scores and higher 
dose of total corticosteroid dose [78]. 
  Metabolic neuroimaging (positron emission tomogra-
phy/PET, MR spectroscopy) and perfusion imaging (single 
photon emission computer tomography/SPECT) can detect 
abnormalities in patients who present exclusively with psy-
chiatric manifestations, but otherwise have normal MRI 
studies. In fact, normal structural MRI studies do not exclude 
active NPSLE as fluorodeoxyglucose-PET (FDG-PET) im-
aging can demonstrate parieto-occipital white matter hy-
pometabolism in 60% to 80% of patients [11, 79-81]. During 
acute NPSLE, FDG-PET reveals white matter abnormalities 
in the prefrontal, anterior cingulate, and inferior parietal re-
gions [11, 82, 83]. Such abnormalities rarely include tempo-
ral regions [79]. Consistent with the vasculopathic nature of 
NPSLE, SPECT and proton MR spectroscopy (
1H-MRS) 
studies suggest that cerebral atrophy and cognitive impair-
ment in SLE patients may be related to chronic diffuse cere-
bral ischemia [17, 76, 84]. MRS is an MR technique that 
determines the biochemical composition or neurometabolites 
of brain tissues noninvasively. Reduced N-acetylaspartate 
(NAA) levels may indicate neuronal injury or death whereas 
increased choline (Cho) levels have been associated with 
gliosis and membrane breakdown. 
1H-MRS shows neurome-
tabolic abnormalities during both active and quiescent peri-
ods of NPSLE, most probably related to neuronal injury or 
loss and demyelination [85, 86] More specifically, SLE pa-
tients with moderate or severe cognitive dysfunction had 
significantly higher Cho/creatine (cr) as determined by 
1H-
MRS compared to those with mild or no cognitive dysfunc-
tion, and SLE patients with active disease had low NAA/cr 
that returned to normal range after disease remission. Con-
versely, patients with active SLE during follow-up devel-
oped significant reduction in NAA/cr [86]. Furthermore, in a 
small study with follow-up after 4-6 years from baseline 
evaluation, all new structural MRI lesions were anatomically 
associated with the previously detected abnormal areas iden-
tified by SPECT and 
1H-MRS [87]. This study is confirmed 
by another group which also found neurometabolic changes, 
specifically increased Cho/cr ratio, in normal appearing 
white matter may predict future appearance of hyperintense 
white matter lesions in SLE [88]. Lesions detected by MRI 
have been shown to correlate with cognitive impairment 
measured by neuropsychological testing in 72% of SLE pa-
tients (Kappa statistics for agreement=0.42, p=0.005) [89]. 
Finally, a recent study demonstrated the close postmortem 
histopathologic association of premortem neurometabolite 
abnormalities in NPSLE [90]. This was a prospective cohort 
study of 168 patients with SLE who had 
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during lupus flare, and at 3 years after enrollment. Correla-
tion of histopathology and imaging showed that: 1) elevated 
Cho levels are independently associated with gliosis, vascu-
lopathy and edema; 2) reduced NAA levels are associated 
with reduced neuronal-axonal density; and 3) presence of 
lactate correlates with necrosis, microhemorrhage, and 
edema [90].  
  Functional MRI (fMRI) is another neuroimaging tech-
nique that has been used to assess for cognitive function in 
SLE. Formal neuropsychological testing and fMRI using 3 
paradigms (continuous performance task, N-back task and 
verb generation) were assessed in a pilot study of 10 patients 
with childhood-onset SLE [91]. Compared to the control 
group, the SLE group demonstrated significantly increased 
activation of brain areas involved in the 3 paradigms. More 
importantly, in the absence of active stimuli, SLE patients 
consistently undersuppressed activity in the expected brain 
area. These findings support the notion that the imbalance 
between active and inhibitory responses to stimuli in child-
hood-onset SLE may be associated with abnormalities in 
white matter connectivity resulting in neuronal network dys-
function. 
  Neuroimaging modalities have greatly advanced the un-
derstanding of NPSLE, which appears to be caused by acute 
and chronic brain injury caused by SLE and are promising 
approaches to elucidate the areas and mechanisms involved 
in NPSLE and specific manifestation as in cognitive dys-
function.  
V. TREATMENT 
  The management of patients with NPSLE is multimodal 
and continues to be a major therapeutic challenge due to the 
broad spectrum of the NPSLE manifestations and limitations 
in diagnostic testing. Currently, only three medications are 
FDA-approved for treatment of SLE in the United States: 
glucocorticoids, aspirin, and hydroxychloroquine. Glucocor-
ticoids are one of the primary therapeutics in the manage-
ment of NPSLE. Treatment choices tend to vary and are tai-
lored to individual patient’s clinical presentation, disease 
severity, and potential pathogenic mechanism. For example, 
thrombosis with the presence of antiphospholipid antibodies 
would indicate the need for anticoagulation. Medication use 
can range from nonsteroidal anti-inflammatory drugs for 
symptomatic relief, anticoagulation for thrombotic diseases, 
to the immunosuppressives for inflammation such as cyclo-
phosphamide, azathioprine, mycophenolate mofetil, and 
methotrexate [92]. Evidence for the efficacy of these thera-
pies is limited to uncontrolled clinical trials and anecdotal 
experience [93]. Adjunctive symptomatic treatment com-
plements these therapies by targeting mood disorders, psy-
chosis, cognitive impairment, seizures or headaches. Mild 
NPSLE may only need symptomatic treatment. Treatment 
strategies should include identification and treatment of any 
secondary causes of CNS dysfunction such as infection, in-
creased intracranial pressure, medication side effects, or pri-
mary psychiatric disorders.  
  Glucocorticoids (e.g. prednisone, methylprednisolone) 
are one of the three FDA-approved drugs for the treatment of 
SLE; currently in the United States, as many as 90% of SLE 
patients are treated with glucocorticoids [11]. The treatment 
with glucocorticoids is widely used in the management of 
seizures, refractory headache, chorea, transverse myelitis and 
other CNS manifestations of SLE. Glucocorticoids are used 
in high doses orally (1-2 mg/kg by mouth daily), or intrave-
nously (usually 1 gram daily for 3 days, followed by daily 
high-dose oral glucocorticoids) for acute and severe flares. 
Many patients require chronic immunosuppressive therapy in 
order to suppress SLE disease activity. Treatment with glu-
cocorticoids carries long-term morbidity and numerous well-
known side effects including dyslipidemia, diabetes, hyper-
tension, accelerated cardiovascular disease, and increased 
susceptibility to infection and osteoporosis. In addition, these 
drugs can induce adverse effects on cognitive functioning 
and psychiatric symptoms [22, 94]. Therefore, in order to 
avoid these potential side effects, patients are administered 
the lowest possible dose of the glucocorticoids.  
  Antimalarial drugs, specifically hydroxychloroquine, 
have suspected immunomodulatory properties that may also 
provide lipid-lowering and antiplatelet effects, thus prevent-
ing thromboembolic events [95]. Hydroxychloroquine can be 
used as maintenance therapy to prevent disease flare and 
may also improve fatigue and possibly cognitive dysfunc-
tion. Hydroxychloroquine is considered the safest of the an-
timalarials and can be continued during pregnancy. The ini-
tial dose is 200 mg daily with a maintenance dosage of 200 
to 400mg daily but less than 6.5 mg/kg ideal body weight. 
The main side effects include irreversible retinopathy and 
glucose-6-phosphate dehydrogenase-induced hemolysis. 
Toxic myopathy can be seen in antimalarial use with the 
presence of curvilinear bodies by electron microscopy in 
muscle biopsy specimens [96]. 
  Anticoagulation is the mainstay of therapy with or with-
out immunosuppressives in NPSLE related to thrombosis 
and the presence of aPL antibodies. Furthermore, anticoagu-
lation may also be used to treat refractory headache in pa-
tients with aPL antibodies. Antiplatelet agents, especially 
aspirin, have also been prescribed in patients with aPL anti-
bodies but without a history of thrombosis. Stratification of 
the risks of thrombosis, smoking cessation and the use of 
protective medications such as aspirin and antimalarials are 
important elements of thrombosis prevention in SLE. 
  Cyclophosphamide is an immunosuppressive and cyto-
toxic alkylating agent used in organ-threatening disease in 
SLE and other autoimmune disorders. Severe NPSLE mani-
festations, mainly CNS involvement like cerebrovascular 
disease due to inflammation and transverse myelitis, has 
been treated with cyclophosphamide. There are different 
regimens of cyclophosphamide, which are mainly studied for 
treatment of lupus nephritis [97]. Cyclophosphamide can be 
given as monthly intravenous (500–1000 mg/m
2) doses for a 
6-month induction period followed by quarterly maintenance 
doses for a period of 2 years [55, 98]; however, studies have 
shown that immunosuppressives with less toxicity can be 
used for maintenance. Monthly intravenous cyclophos-
phamide was found to be superior to methylprednisolone in a 
small, randomized, clinical trial in controlling refractory 
seizures, peripheral and cranial neuropathy, and optic neuri-
tis with a similar incidence of new infections [99]. In the 
Euro-Lupus Nephritis trial, lower dosage of intravenous   
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months for treatment of proliferative lupus nephritis.   
This study found comparable clinical results of this low-dose 
intravenous cyclophosphamide (cumulative dose of 3 gram) 
followed by azathioprine and the high-dose group   
(6 monthly pulse cyclophosphamide followed by 2 quarterly 
pulses) [100]. The most important side effects of cyclophos-
phamide include susceptibility to a variety of opportunistic 
infections, hemorrhagic cystitis from acrolein (toxic metabo-
lite), increased risk of malignancy (non-Hodgkin lymphoma, 
leukemia, and transitional cell carcinoma of the bladder), and 
potential ovarian or testicular failure [101]. Due to the toxic-
ity of cyclophosphamide, the current view is that cyclophos-
phamide should be used for shorter duration with a lower 
dose if possible and not be continued for maintenance ther-
apy. Immunosuppressives with better side effect profile, such 
as mycophenolate mofetil (MMF), have been used frequently 
for maintenance and even initial treatment of NPSLE mani-
festations. 
  Other agents such as azathioprine and methotrexate have 
been used in systemic lupus erythematosus to treat a variety 
of manifestations or have been used as glucocorticoid-
sparing agents, but controlled trials are lacking [102]. 
Azathioprine, methotrexate, and MMF are antimetabolites, 
which inhibit de novo synthesis of purine and/or pyrimidine 
[103]. Azathioprine is a prodrug that is rapidly and almost 
completely converted to 6-mercaptopurine (6-MP) and 
methylnitroimidazole. Further metabolism of 6-MP inhibits 
several enzymes of purine synthesis. Methotrexate and its 
polyglutamate derivatives suppress inflammatory response 
through release of adenosine, suppress immune response by 
inducing the apoptosis of activated T lymphocytes and inhib-
iting the synthesis of both purines and pyrimidines. MMF is 
a prodrug of mycophenolic acid (MPA) and an inhibitor of 
inosine-5’-monophosphate dehydrogenase. MPA depletes 
guanosine nucleotides preferentially in T and B lymphocytes 
and inhibits their proliferation, thereby suppressing cell-
mediated immune response and antibody formation. MPA 
also inhibits the expression of adhesion molecules and the 
recruitment of immune cells (lymphocytes and monocytes) 
into sites of inflammation. MMF has been used to reduce 
acute and chronic rejection in allograft recipients. MMF 
showed a significantly higher remission rate than intravenous 
cyclophosphamide in renal lupus [104]. However, in a large 
international randomized controlled trial, MMF (target dos-
age 3 grams/day orally) and intravenous cyclophosphamide 
(0.5 to 1 gram/meter
2 in monthly pulses) have similar effi-
cacy to short-term induction therapy (24 weeks) for active 
lupus nephritis [105]. Of note, more Black and Hispanic pa-
tients responded to MMF than intravenous cyclophos-
phamide [106]. MMF has also shown to be efficacious in 
non-SLE patients with multiple sclerosis and optic neuritis 
by reducing the relapse rate [107, 108]. These noncytotoxic 
immunosuppressives are more commonly used in NPSLE 
patients with peripheral nervous system involvement such as 
peripheral and cranial neuropathy. Furthermore, MMF may 
be used as maintenance therapy after initial treatment with 
cyclophosphamide in patients with severe NPSLE. 
  Intravenous immunoglobulin (IVIG), plasmapheresis, 
and rituximab have been used in central nervous system 
manifestations unresponsive to glucocorticoid therapy and/or 
cytotoxic therapy. IVIG has immunomodulatory effects by 
interaction with the anti-idiotypic network, interference with 
the complement and cytokines’ network, cytolysis of target 
cells through complement or antibody-dependent cell-
mediated cytotoxicity and induction of apoptosis of target 
cells through Fc receptors, neutralization of pathogenic anti-
bodies and modulation of the activation and co-stimulatory 
molecules affecting differentiation of T cells, B cells, and 
dendritic cells [109]. IVIG also suppresses the expansion of 
auto-reactive B lymphocytes through signaling of the 
FcgRIIB, idiotype-mediated inhibition of B cell receptors 
and neutralization of cytokines such as the B cell survival 
factors. IVIG has been given as 2 gm/kg with divided doses 
over two to five days to treat thrombocytopenia, renal dis-
ease, central nervous system manifestations, and pregnancy 
loss associated with the presence of antiphospholipid   
antibodies [110]. Plasmapheresis, administered four to six 
sessions over one to two weeks, may be another option for 
the treatment of NPSLE manifestations [92]. The rationale of 
plasma exchange is based on the rapid removal of circulating 
pathogenic autoantibodies, immunoglobulins, immune com-
plexes, and toxins. One study showed a significant elevation 
of peripheral CD4+ CD25 
high FoxP3
+ suppressor T cells in 
SLE patients treated with repeated plasmapheresis resulting 
in significant clinical improvements, thereby suggesting the 
increase in regulatory T cells may be one of the reasons of 
the beneficial effects of plasmapheresis in SLE patients 
[111]. Rituximab, chimeric anti-CD20 monoclonal antibod-
ies that deplete CD20+ B cell, has shown to be efficacious in 
treatment of refractory SLE in case reports including those 
with transverse myelitis and CNS vasculitis [112, 113]. 
Adjunctive Medications Commonly Used for Sympto-
matic Treatment 
  NPSLE manifestations, such as seizures and headaches, 
should also be treated with a combination of symptomatic 
and immune-modulating therapy. Seizures are managed with 
standard anticonvulsants. Although these medications have 
been implicated in drug-induced lupus, they do not appear to 
alter idiopathic disease. The nonsteroidal anti-inflammatory 
drugs (NSAIDs) suppress mild acute inflammation alleviat-
ing musculoskeletal manifestations, fatigue and fever. 
NSAIDs can alleviate migraine headache frequently seen in 
patients with SLE. However, chronic NSAIDs use can also 
aggravate headache. They may be administered alone or 
given in combination with glucocorticoids, allowing a de-
crease in glucocorticoid dosage. There are numerous options 
when choosing NSAIDs and effectiveness varies widely, 
therefore doses should be individualized. The adverse effects 
of NSAIDs include nonsteroidal-induced nephropathy, gas-
trointestinal bleeding, and ibuprofen-induced aseptic menin-
gitis [92]. Psychotropic medications (antidepressants, anx-
iolytics, and atypical antipsychotics) may have an important 
adjunctive role in SLE patients with affective disorder or 
psychosis. There is no standardized treatment in lupus psy-
chosis. The treatment for acute psychosis includes a combi-
nation of antipsychotic medications as symptomatic treat-
ment and glucocorticoids to control underlying disease activ-
ity [114, 115]. Steroid-induced psychosis can be seen in pa-
tients already on this medication. A temporal relationship 
between the initiation of glucorticoids and psychiatric 
events, and the resolution of psychiatric symptoms after re-
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nosis of steroid-induced psychosis. Pharmacologic treatment 
aimed at cognitive enhancement has not been studied in 
NPSLE. However, the regular use of aspirin in older SLE 
patients with diabetes was associated with improved cogni-
tive function in the SALUD study [116]. On the other hand, 
consistent glucocorticoid use, which may be a surrogate of 
more active or severe disease, is associated with decline in 
cognitive function. 
 Nonpharmacological approaches, like cognitive rehabili-
tation programs or psychological group intervention may be 
important in SLE patients with psychiatric disorders such as 
depression, anxiety or cognitive dysfunction with impaired 
attention, concentration and memory [117]. The heterogene-
ity of the neuropsychological manifestations and the affected 
cognitive domains has led to a paucity of controlled clinical 
trials for cognitive rehabilitation of SLE patients. Thus, the 
current therapeutic approach is not based on empirical find-
ings, but on clinical experience and small clinical studies. 
VI. FUTURE PERSPECTIVES 
  Although the above therapeutics may demonstrate sig-
nificant benefits for NPSLE patients even with severe and 
otherwise refractory disease, there is unfortunately no cure 
for SLE. A variety of new biological agents for treatment of 
SLE (non-NPSLE) are being tested in randomized clinical 
trials. Belimumab, a human monoclonal antibody that targets 
B lymphocyte stimulator (BLys), is the first successful late-
stage (Phase 3) trial for treatment of SLE, which showed a 
clinically and statistically significant reduction in SLE dis-
ease activity and flare rates, steroid use, and prolonged time-
to-first lupus flare in patients with seropositive SLE or hav-
ing positive antinuclear antibodies (ANA>1:80 and/or anti-
double-stranded DNA >30 IU/mL) [118]. The second be-
limumab study also showed reduction in SLE disease activ-
ity and severe lupus flare rates but no improvement in physi-
cian global assessment or reduction in steroid use as seen in 
the BLISS-52 study [119]. The adverse events and infection 
rates were comparable in the belimumab and placebo groups. 
Gene therapy and stem cell transplantation are also being 
investigated as novel therapies for SLE. However, due to the 
vast heterogeneity of the NPSLE manifestations, the treat-
ment selection will need to be individualized based on both 
NPSLE and non-NPSLE clinical manifestations. Prospective 
multicenter studies are greatly needed to improve our knowl-
edge and to help establish guidelines for the treatment of 
NPSLE manifestations.  
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